Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN – Get Free Report) have received a consensus rating of “Hold” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $24.00.
Several analysts have recently issued reports on SLN shares. Chardan Capital cut Silence Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 21st. William Blair downgraded shares of Silence Therapeutics from an “outperform” rating to a “hold” rating in a research note on Monday, October 19th. HC Wainwright lowered shares of Silence Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $75.00 to $20.00 in a research report on Wednesday, October 21st. Morgan Stanley lifted their price objective on shares of Silence Therapeutics from $25.00 to $32.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a report on Thursday, October 15th.
Get Our Latest Stock Report on SLN
Silence Therapeutics Price Performance
Shares of Silence Therapeutics stock opened at $19.81 on Friday. The business has a 50 day simple moving average of $15.15 and a two-hundred day simple moving average of $10.05. The stock has a market capitalization of $1.23 billion, a P/E ratio of -18.51 and a beta of 1.34. Silence Therapeutics has a 12 month low of $4.19 and a 12 month high of $19.86.
Silence Therapeutics (NASDAQ:SLN – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.13). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 56.32%. As a group, research analysts anticipate that Silence Therapeutics will post -0.81 EPS for the current fiscal year.
Institutional Trading of Silence Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Soleus Capital Management L.P. lifted its holdings in Silence Therapeutics by 278.7% in the third quarter. Soleus Capital Management L.P. now owns 2,385,700 shares of the company’s stock valued at $26,076,000 after acquiring an additional 1,755,700 shares during the period. Toronto Dominion Bank purchased a new stake in shares of Silence Therapeutics during the 3rd quarter worth $5,314,000. 5AM Venture Management LLC acquired a new position in shares of Silence Therapeutics during the 2nd quarter worth $5,228,676. Goldman Sachs Group Inc. grew its stake in shares of Silence Therapeutics by 196.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 462,831 shares of the company’s stock worth $5,059,000 after purchasing an additional 306,902 shares during the period. Finally, Aberdeen Group plc acquired a new position in shares of Silence Therapeutics during the 3rd quarter worth $2,207,000. Hedge funds and other institutional investors own 98.73% of the company’s stock.
Silence Therapeutics Company Profile
Silence Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce production of specific disease-related proteins. Its proprietary mRNAi GOLD platform is designed to create small interfering RNA (siRNA) medicines, including treatments that target genes expressed in the liver. The company’s research and development programs have included zerlasiran, which targets lipoprotein(a), a risk factor for cardiovascular disease, and divesiran, investigated for blood disorders.
Further Reading
- Five stocks we like better than Silence Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
